Literature DB >> 20952733

Scintigraphic assessment of salivary gland function in a rat model.

Andreas Pfestroff1, Felix Müller, Damiano Librizzi, Behfar Eivazi, Martin Behe, Helmut Hoeffken, Thomas M Behr, Afshin Teymoortash.   

Abstract

BACKGROUND: Salivary gland dysfunction with xerostomia is a major clinical problem without a causal therapy in most cases. The development of an animal model for scintigraphic assessment of salivary gland function has great clinical relevance for the investigation of promising new diagnostic and therapeutic strategies for chronic salivary gland diseases. This study reports the first experiences with scintigraphic analyses of salivary gland function in a rat model.
MATERIALS AND METHODS: Anatomical and scintigraphic studies were performed for topographic differentiation of major salivary glands of Wistar rats. (⁹⁹m)technetium pertechnetate salivary gland scanning was performed, appropriate regions of interest were determined and the gland-to-background ratio was examined for the evaluation of salivary gland function.
RESULTS: The quantitative analysis of salivary gland scintigraphy revealed a reliable comparison of major salivary glands on both sides with the gland-to-background ratio ranging from 1.26 to 1.94 with an average of 1.51.
CONCLUSION: This model seems to be appropriate for functional studies in an experimental setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952733

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  2 in total

1.  Radioprotective Effect of Thymol Against Salivary Glands Dysfunction Induced by Ionizing Radiation in Rats.

Authors:  Seyed Mohammad Abedi; Fateme Yarmand; Mina Motallebnejad; Maryam Seyedmajidi; Dariush Moslemi; Ali Bijani; Seyed Jalal Hosseinimehr
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

2.  Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial.

Authors:  Afshin Teymoortash; Andreas Pfestroff; Andrea Wittig; Nora Franke; Stephan Hoch; Susanne Harnisch; Carmen Schade-Brittinger; Helmut Hoeffken; Rita Engenhart-Cabillic; Markus Brugger; Konstantin Strauch
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.